Eli Lilly and Company (LLY) on Thursday reported positive topline results from the Phase III TRIUMPH-1 trial evaluating Retatrutide in adults with obesity or overweight, at least one weight-related comorbidity, and without diabetes. At 80 weeks, all doses of retatrutide met the trial's primary and...
Boston Scientific (BSX) announced positive results from the FRACTURE Investigational Device Exemption trial evaluating the use of the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter to treat patients with severely calcified coronary artery disease. The company said the study met its primary safety...
Sanofi SA (SNY) reported positive data from the Phase 2 ElevAATe study of efdoralprin alfa in adult patients with alpha-1 antitrypsin deficiency-related emphysema. Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic condition characterized by low levels or absence of alpha-1 antitrypsin, a protein...
Monday, Design Therapeutics, Inc. (DSGN) announced positive biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia. The study observed both dose-dependent increases in FXN levels and dose-dependent improvements across multiple...
Protara Therapeutics, Inc. (TARA) on Friday announced positive updated 12-month data from the Phase 2 ADVANCED-2 study evaluating TARA-002 in certain patients with non-muscle invasive bladder cancer (NMIBC). The study is evaluating intravesical TARA-002 in patients with carcinoma in situ who are Bacillus...
Thursday, Biogen Inc. (BIIB) announced compelling topline results from the Phase 2 CELIA study evaluating diranersen in participants with early Alzheimer's disease. Notably, the study did not meet its primary endpoint assessing dose response for change from baseline on the Clinical Dementia Rating-Sum...
REGENXBIO Inc. (RGNX) on Thursday announced positive topline and interim functional data from the pivotal Phase III AFFINITY DUCHENNE trial of RGX-202, the company's gene therapy candidate for Duchenne Muscular Dystrophy. The trial evaluated RGX-202 in 31 ambulatory boys aged 1 year of age and older....
AstraZeneca plc (AZN) on Thursday said an interim analysis of the Phase III VOLGA trial showed that perioperative treatment with Imfinzi combined with neoadjuvant enfortumab vedotin (EV) significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer compared...
Wednesday, Eli Lilly and Company (LLY) announced results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy. In SURMOUNT-MAINTAIN trial, both...
Astellas Pharma Inc. (ALPMY) on Tuesday reported results from a post hoc analysis of its GATHER1 and GATHER2 pivotal studies, showing that treatment with IZERVAY reduced the risk of patients progressing to loss of driving eligibility compared with sham over 24 months in geographic atrophy (GA) associated...
VistaGen Therapeutics Inc (VTGN) on Tuesday announced preliminary positive data from the ongoing open-label extension portion of its Phase 3 PALISADE-3 study evaluating fasedienol for the acute treatment of social anxiety disorder. The study assessed changes from baseline on the Liebowitz Social Anxiety...
Tuesday, Alkermes plc (ALKS) announced positive topline results from the REVITALYZ phase 3 study, evaluating the investigational use of LUMRYZ extended-release oral suspension in adults with idiopathic hypersomnia. The company stated that LUMRYZ met the primary endpoint by showing statistically significant...
Artiva Biotherapeutics, Inc. (ARTV) on Friday announced positive initial data from ongoing studies evaluating its cell therapy candidate AlloNK in combination with rituximab for patients with autoimmune diseases. The company's shares were up more than 10% in pre-market trading.
Tuesday, Johnson & Johnson (JNJ) announced Phase 2b data from two studies evaluating JNJ-4804 in patients with moderately to severely active ulcerative colitis or Crohn's disease. In the DUET-CD study, JNJ-4804a demonstrated higher clinical remission rates and endoscopic response rates than golimumab...
Johnson & Johnson (JNJ) on Tuesday announced positive results from the Phase 3 FUZION study evaluating TREMFYA in adults with active perianal fistulizing Crohn's disease. The study met its primary endpoint of combined fistula remission at Week 24, defined as complete closure of all external fistula...
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.